Join the Parkinson's Action Network (PAN), June 24, 2010 from 2:00 pm - 4:30 pm EDT, for an exciting and educational look at the drug development pipeline. From your computer, you will join others from across the country for a 2 ½ hour Webcast exploring the path in which drugs and therapies make it from the laboratory to the hands of patients.
The "Emerging Therapies: From Microscope to Marketplace" Webcast will feature panelists from the research, patient, corporate, and approval communities, all of which interact in unique ways throughout the pipeline. Through short presentations and questions from the Webcast audience, live audience, and the moderator, the panel will provide insight into the development process and how their work overlaps and affects the others.
The panel will be moderated by Howard Federoff, M.D., Ph.D., Executive Vice President for Health Science and Executive Dean of the School of Medicine at Georgetown University.
• James P. Bennett, Jr., M.D., Ph.D., Chair, Department of Neurology and Founding Director of the Virginia Commonwealth University Parkinson’s Disease and Movement Disorders Multidisciplinary Research and Clinical Center
o Dr. Bennett represents basic research in the development pipeline
• Story Landis, Ph.D., Director, National Institute of Neurological Disorders and Stroke (NINDS)
o Dr. Landis represents the translation from basic to clinical research in the development pipeline
• Raymond T. Bartus, Ph.D., Executive Vice President and Chief Scientific Officer, Ceregene, Inc.
o Dr. Bartus represents the industry perspective in the development pipeline
• Jackie Hunt Christensen, PAN Minnesota State Coordinator and Clinical Trial Participant
o Jackie represents the clinical trial participant in the development pipeline
• Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, Food and Drug Administration
o Dr. Woodcock represents the role of FDA in the development pipeline
PAN has focused on the drug development pipeline for many years. Because of this work, PAN is now a leader of this cause, pushing for additional funding for translational research and innovative ways to speed up the time between discovery and approval of new drugs and therapies. The Webcast will offer an excellent opportunity for members of the Parkinson's community, and other advocacy communities, to learn more about the drug development process, the problems agencies, patients, and corporations face, and what is being done to speed it up.
Although a formal RSVP is not required for the Webcast, the surest way to stay updated for this event is to join PAN's e-mail list
. You will receive up-to-date information on the Webcast as the event nears. On June 24, simply visit PAN's home page
and you will be directed to the Webcast. Mark your calendars now!